Cadrenal Therapeutics Inc.

Contributing Author

Recent Articles by Cadrenal Therapeutics Inc.

Dec-17	Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 CVKD GlobeNewswire
Dec-11	Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) CVKD GlobeNewswire
Dec-01	Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors CVKD GlobeNewswire
Nov-19	Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award CVKD GlobeNewswire
Nov-10	Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update CVKD GlobeNewswire
Sep-29	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 CVKD GlobeNewswire
Sep-15	Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors CVKD GlobeNewswire